{"organizations": [], "uuid": "60db64252c66cafa0d9d66974f13d128e026e970", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-genentech-phase-iii-imblaze370-stu/brief-genentech-phase-iii-imblaze370-study-did-not-meet-primary-endpoint-compared-to-regorafenib-idUSASC0A1A8", "country": "US", "domain_rank": 408, "title": "BRIEF-Genentech Phase III IMblaze370 Study Did Not Meet Primary Endpoint Compared To Regorafenib", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-10T08:07:00.000+03:00", "replies_count": 0, "uuid": "60db64252c66cafa0d9d66974f13d128e026e970"}, "author": "", "url": "https://www.reuters.com/article/brief-genentech-phase-iii-imblaze370-stu/brief-genentech-phase-iii-imblaze370-study-did-not-meet-primary-endpoint-compared-to-regorafenib-idUSASC0A1A8", "ord_in_thread": 0, "title": "BRIEF-Genentech Phase III IMblaze370 Study Did Not Meet Primary Endpoint Compared To Regorafenib", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "regorafenib reuters", "sentiment": "none"}, {"name": "genentech", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 10 (Reuters) -\n* GENENTECH PROVIDES UPDATE ON PHASE III STUDY OF TECENTRIQ (ATEZOLIZUMAB) AND COTELLIC (COBIMETINIB) IN PEOPLE WITH HEAVILY PRE-TREATED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER\n* GENENTECH - PHASE III IMBLAZE370 STUDY EVALUATING COMBINATION OF TECENTRIQ AND COTELLIC DID NOT MEET PRIMARY ENDPOINT OF OVERALL SURVIVAL COMPARED TO REGORAFENIB\n* GENENTECH- RESULTS FROM IMBLAZE370 SHOWED TREATMENT WITH TECENTRIQ ALONE DID NOT PROVIDE MEANINGFUL CLINICAL BENEFIT COMPARED TO REGORAFENIB Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-05-10T08:07:00.000+03:00", "crawled": "2018-05-10T08:25:28.002+03:00", "highlightTitle": ""}